Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 3,530 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: biospecimen Collection Clear all

Conditions: Pediatric Central Nervous System Tumor, Central Nervous System Tumor, Discordant Twin, Somatic Mutation
Interventions: Biospecimen collection, Questionnaire Administration; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Substance Abuse
Interventions: Blood draw; Procedure
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v6, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 10
States / cities: Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 6 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 180
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more

Conditions: Uterine Fibroids
Interventions: telepristone acetate 12 mg, telepristone acetate 3 mg, telepristone acetate 6 mg, telepristone acetate 24 mg; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Miami Gardens, Florida • Houston, Texas

Conditions: Prostate Cancer
Interventions: MyProstateScore; Diagnostic Test
Lead sponsor: LynxDx; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Rheumatoid Arthritis, Healthy Controls
Interventions: Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment; Other
Lead sponsor: Duke University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Tazemetostat Hydrobromide, Topotecan Hydrochloride; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • Newport Beach, California • Sacramento, California + 9 more

Conditions: Diffuse Large B Cell Lymphoma, Solid Tumor Cancer
Interventions: Not listed
Lead sponsor: OWKIN; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Game Module, Smoke Free smartphone application; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Renal Failure
Interventions: Blood Draw; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, DDX5 Degrader FL118, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Rituximab, Tafasitamab; Procedure · Biological
Lead sponsor: Timothy Voorhees; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Hillsborough, North Carolina • Columbus, Ohio + 1 more

Conditions: Neonatal SEPSIS
Interventions: Blood Collection Preterm, Blood Collection Term, Adult Blood collection; Other
Lead sponsor: University of Florida; Other
Eligibility: 23 Weeks to 42 Weeks
Enrollment: 293 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Non-hematologic Cancer
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 55
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 43 more

Conditions: Congenital Disease
Interventions: Congenital Heart Disease Surgery; Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 3 Days to 2 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Gastroesophageal Reflux Disease, Barrett's Esophagus, Esophagus Adenocarcinoma
Interventions: Primary Care Provider Survey, Gastroenterologist Survey, Patient Survey; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 725 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Dallas, Texas

Conditions: CMV
Interventions: illumigene CMV assay, illumipro-10; Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: Up to 20 Days
Enrollment: 1,615 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Birmingham, Alabama • Salt Lake City, Utah

Conditions: BK Virus Infection, Kidney Transplant; Complications
Interventions: Blood samples: Main Study group, Data Collection, Urine Sample- Main Study group, Urine sample- Sub-study group, Blood sample: Sub-study group; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy
Interventions: Blood draw; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions: Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Biospecimen Collection, Single Photon Emission Computed Tomography; Drug · Procedure · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hiv
Interventions: HIVD+/R+; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 26
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 17 more

Search by objective public record fields.

Somatic Mosaicism in Twins Discordant for Childhood Cancer

The Genetic Basis for Vulnerability to Substance Abuse

A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Extension of Study ZPV-200

MyProstateScore Equivalency With and Without DRE

MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

Pilot Trial of a Game Embedded in a Smartphone App for Smoking Cessation

A Study of Cytokine and Inflammatory Markers in Patients With Chronic Renal Failure

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Microfluidic Assessment of Clinical Outcomes in Preterm Newborns

Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Kids Intestinal Dysfunction in Congenital Heart Disease: the Kind Heart Study

Survey Study on Barrett's Esophagus Screening

Detection of Cytomegalovirus Virus in Neonates

Immune Registry for BK in Kidney Transplant Recipients

Investigations Regarding B-cell Subsets in Humans

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients